Identifying Insulin Treatment Responders with a Composite Measure: Beyond Hba1c < 7% in Patients with Type 2 Diabetes.
CONCLUSION: Composite HbA1c measures identified more patients with clinically meaningful responses to therapy than the broadly accepted HbA1c <7% and may be useful in assessing clinical trials, clinical care, and quality measures.
PMID: 29065720 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Clinical Trials | Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Humalog | Insulin | Research